


Pharmaceuticals & Biotechnology | Small Cap
BPL Ltd, operating in the consumer durables sector, demonstrates a mixed financial performance. The company shows strong solvency and profitability, driven by a healthy equity position and solid margins. Revenue and asset growth are positive, indicating market expansion. However, liquidity is a concern, with low current and cash ratios. Efficiency is also mixed, with good inventory management but challenges in asset utilization and receivable collection. While interest coverage is adequate, the absence of dividend coverage is a notable weakness. Overall, BPL showcases potential with its growth and profitability, but needs to address liquidity and efficiency to ensure sustainable financial health. Recent capital expenditure may be a cause for concern.
BPL Ltd, operating in the consumer durables sector, demonstrates a mixed financial performance. The company shows strong solvency and profitability, driven by a healthy equity position and solid margins. Revenue and asset growth are positive, indicating market expansion. However, liquidity is a concern, with low current and cash ratios. Efficiency is also mixed, with good inventory management but challenges in asset utilization and receivable collection. While interest coverage is adequate, the absence of dividend coverage is a notable weakness. Overall, BPL showcases potential with its growth and profitability, but needs to address liquidity and efficiency to ensure sustainable financial health. Recent capital expenditure may be a cause for concern.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-17.81
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
-30.53
P/B RATIO
1.09
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
3.38
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-116.87
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹53.42 as on Aug 6, 2026.
The company demonstrates strong revenue and asset growth, along with a significant increase in operating profit. However, earnings per share and net income growth are negative, indicating potential issues with profitability despite revenue gains. Overall, the company is expanding its operations, but profitability needs to catch up with revenue growth. The company has potential to grow, but profitability is a major concern.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 36.52 | 27.21 | 17.96 | -0.31 | |
| Operating Profit Growth Rate | 4446.15 | 142.3 | -12.57 | -138.5 | |
| Earnings Per Share (EPS) Growth | -61.13 | 168.93 | -98.19 | -3600 | |
| Asset Growth Rate | 11.73 | 2.86 | -0.56 | 16.44 | |
| Net Income Growth Rate | -60.93 | 165.02 | -99.25 | -8650 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.43 | Neutral | 7.00 | 1.40 | 4.00 |
| 5 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 6 | BPL Ltd | 5.46 | -30.53 | Neutral | -4.82 | -1.69 | -8.55 |
| 7 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 8 | Quest Laboratories Ltd | 5.27 | 9.84 | Neutral | 18.00 | 9.16 | 15.00 |
| 9 | Sotac Pharmaceuticals Ltd | 5.27 | 18.18 | Neutral | 18.00 | 4.45 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.34 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral